INVOKANA® (canagliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

INVOKANA® is not recommended in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

WARNINGS and PRECAUTIONS

DRUG INTERACTIONS

USE IN SPECIFIC POPULATIONS

OVERDOSAGE

ADVERSE REACTIONS

Please see full Prescribing Information and Medication Guide.

044334-151207

Janssen Pharmaceuticals, Inc.

Canagliflozin is licensed from
Mitsubishi Tanabe Pharma Corporation.

© Janssen Pharmaceuticals, Inc., 2016. All rights reserved.
January 2016 044746-151215